Wall Street brokerages expect Acer Therapeutics Inc (NASDAQ:ACER) to announce earnings of ($0.53) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Acer Therapeutics’ earnings. The highest EPS estimate is ($0.47) and the lowest is ($0.57). Acer Therapeutics reported earnings of ($1.09) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 51.4%. The business is scheduled to report its next quarterly earnings report on Monday, November 12th.
According to Zacks, analysts expect that Acer Therapeutics will report full year earnings of ($2.22) per share for the current year, with EPS estimates ranging from ($2.29) to ($2.05). For the next financial year, analysts forecast that the company will post earnings of ($2.20) per share, with EPS estimates ranging from ($2.93) to ($1.41). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Acer Therapeutics.
Acer Therapeutics (NASDAQ:ACER) last released its quarterly earnings results on Monday, August 13th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.09).
Shares of ACER traded down $0.39 during trading hours on Monday, reaching $24.84. 9,856 shares of the stock traded hands, compared to its average volume of 31,331. Acer Therapeutics has a 52 week low of $11.36 and a 52 week high of $34.10. The firm has a market capitalization of $299.73 million, a P/E ratio of -6.47 and a beta of 2.45.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. increased its stake in shares of Acer Therapeutics by 2,015.8% in the second quarter. BlackRock Inc. now owns 7,786 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 7,418 shares in the last quarter. Neuberger Berman Group LLC purchased a new position in shares of Acer Therapeutics in the first quarter worth about $385,000. Acuta Capital Partners LLC purchased a new position in shares of Acer Therapeutics in the second quarter worth about $2,360,000. Finally, Heartland Advisors Inc. increased its stake in shares of Acer Therapeutics by 177.0% in the second quarter. Heartland Advisors Inc. now owns 154,000 shares of the biopharmaceutical company’s stock worth $3,326,000 after purchasing an additional 98,400 shares in the last quarter. Institutional investors and hedge funds own 7.43% of the company’s stock.
About Acer Therapeutics
Acer Therapeutics Inc, a pharmaceutical company, develops therapies for the treatment of rare diseases with critical unmet medical needs. Its product candidates include Celiprolol for the treatment of vascular Ehlers-Danlos syndrome; and ACER-001 for the treatment of urea cycle disorders and maple syrup urine disease.
Featured Story: Compound Annual Growth Rate (CAGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.